Canada Warns About Stop-Smoking Drug July 3, 2008
News Summary
Health Canada has echoed a U.S. Food and Drug Administration (FDA) warning about suicide and depression linked to a leading stop-smoking drug, the Toronto Globe and Mail reported June 21.
The agency warned that Champix -- known as Chantix in the U.S. -- was linked to 226 reports of neuropsychiatric problems in Canada in the first year after it hit the marketplace. "A number of patients taking Champix have experienced unusual feelings of agitation, depressed mood, hostility, changes in behavior or impulsive or disturbing thoughts such as thoughts of self-harm or harm to others," according to Health Canada.
Pfizer Canada, the drug's manufacturer, stated, "As with any new drug, you need to be monitored for side effects, but it's safe and efficacious."
COMMENTS ON THIS ARTICLE: